<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415623</url>
  </required_header>
  <id_info>
    <org_study_id>A0531085</org_study_id>
    <nct_id>NCT00415623</nct_id>
  </id_info>
  <brief_title>A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient</brief_title>
  <official_title>A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The changes in the trough systolic blood pressure from the baseline were assessed after 8
      weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)</measure>
    <time_frame>Baseline to Week 6 and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)</measure>
    <time_frame>Baseline to Week 6 and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by &gt;= 10 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by &gt;= 10 mmHg at Both Weeks 6 and 8</measure>
    <time_frame>Week 6 and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8</measure>
    <time_frame>Week 6 and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg</measure>
    <time_frame>Baseline, Week 4, and Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5mg/ day</description>
    <arm_group_label>Amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 10mg/ day</description>
    <arm_group_label>Amlodipine 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated Hypertensive Patients: An systolic blood pressure of &gt;=160 mmHg or diastolic
             blood pressure &gt;=100mmHg.

          -  Treated Hypertensive Patients: An systolic blood pressure of &gt;=140 mmHg or diastolic
             blood pressure of &gt;= 90 mmHg.

          -  Patients with insufficient response to 5 mg of amlodipine in the screening period:Two
             successive systolic blood pressure measurements at Visit 4 (Week -2) and Visit 5 (Week
             0 = baseline) &gt;=140 mmHg

          -  Patients with a screening treatment compliance rate &gt;= 80%

        Exclusion Criteria:

          -  Subjects with secondary hypertension (renal disease, pheochromocytoma, and Cushing's
             syndrome, etc.), severe hypertension (systolic blood pressure of 180 mmHg or higher,
             or diastolic blood pressure of 110 mmHg or higher), and malignant hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kasuya-gun</city>
        <state>Fujuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koga</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaidou</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Iruma</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koshigaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sumida</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0531085&amp;StudyName=A%20Comparative%20Study%20Between%20Amlodipine%2010mg%20And%205mg%20With%20Hypertension%20For%20Whom%205mg%20Is%20Insufficient</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <results_first_submitted>October 16, 2008</results_first_submitted>
  <results_first_submitted_qc>December 5, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2008</results_first_posted>
  <last_update_submitted>December 5, 2008</last_update_submitted>
  <last_update_submitted_qc>December 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-four (24) centers in Japan</recruitment_details>
      <pre_assignment_details>Consent was taken from 414 patients, 356 patients who met the screening criteria received amlodipine 5 mg. After the 8 weeks of screening treatment, patients who met the entry criteria for double-blind period were randomized to either the amlodipine 10 mg group or the amlodipine 5 mg group at a ratio of 1:1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine 5 mg</title>
          <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine 10 mg</title>
          <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine 5 mg</title>
          <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine 10 mg</title>
          <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>partcipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 8</title>
        <description>Mean change in the trough SBP</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 8</title>
          <description>Mean change in the trough SBP</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-8.8" upper_limit="-5.2"/>
                    <measurement group_id="O2" value="-13.7" lower_limit="-15.4" upper_limit="-12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough SBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>-4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8</title>
        <description>Mean change in the trough DBP</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8</title>
          <description>Mean change in the trough DBP</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" lower_limit="-3.9" upper_limit="-1.4"/>
                    <measurement group_id="O2" value="-6.8" lower_limit="-8.0" upper_limit="-5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough DBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)</title>
        <description>Arithmetic mean of Week 6 &amp; Week 8 by patient for “Change from baseline in SBP at Week 6” and “Change from baseline in SBP at Week 8”</description>
        <time_frame>Baseline to Week 6 and Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)</title>
          <description>Arithmetic mean of Week 6 &amp; Week 8 by patient for “Change from baseline in SBP at Week 6” and “Change from baseline in SBP at Week 8”</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" lower_limit="-8.4" upper_limit="-5.2"/>
                    <measurement group_id="O2" value="-13.9" lower_limit="-15.5" upper_limit="-12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough SBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)</title>
        <description>Arithmetic mean of Week 6 &amp; Week 8 by patient for “Change from baseline in DBP at Week 6” and “Change from baseline in DBP at Week 8”</description>
        <time_frame>Baseline to Week 6 and Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)</title>
          <description>Arithmetic mean of Week 6 &amp; Week 8 by patient for “Change from baseline in DBP at Week 6” and “Change from baseline in DBP at Week 8”</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-3.6" upper_limit="-1.4"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-7.6" upper_limit="-5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough DBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8</title>
        <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
        <time_frame>Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8</title>
          <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (&lt;=64, &gt;=65) as a factor. The significance level was 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8</title>
        <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
        <time_frame>Week 6 and Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8</title>
          <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (&lt;=64, &gt;=65) as a factor. The significance level was 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.28</ci_lower_limit>
            <ci_upper_limit>8.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by &gt;= 10 mmHg at Week 8</title>
        <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
        <time_frame>Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by &gt;= 10 mmHg at Week 8</title>
          <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (&lt;=64, &gt;=65) as a factor. The significance level was 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>4.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by &gt;= 10 mmHg at Both Weeks 6 and 8</title>
        <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
        <time_frame>Week 6 and Week 8</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5 mg</title>
            <description>One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10 mg</title>
            <description>Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by &gt;= 10 mmHg at Both Weeks 6 and 8</title>
          <description>Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for &lt;=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for &gt;=65 years old</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (&lt;=64, &gt;=65) as a factor. The significance level was 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.12</ci_lower_limit>
            <ci_upper_limit>8.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg</title>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Plasma concentration obtained after temporarily dosing discontinuation or not matched with the following conditions were excluded from the analysis; Steady-state condition: at least 80% drug compliance from the previous visit to the day of sampling; Trough condition: samples taken within ±10% of 24 hours from last dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>After once daily administration of amlodipine 5 mg for 8 weeks in the screening period</description>
          </group>
          <group group_id="O2">
            <title>Week 4</title>
          </group>
          <group group_id="O3">
            <title>Week 8</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg</title>
          <population>Plasma concentration obtained after temporarily dosing discontinuation or not matched with the following conditions were excluded from the analysis; Steady-state condition: at least 80% drug compliance from the previous visit to the day of sampling; Trough condition: samples taken within ±10% of 24 hours from last dosing.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" lower_limit="6.5" upper_limit="7.5"/>
                    <measurement group_id="O2" value="6.83" lower_limit="6.3" upper_limit="7.4"/>
                    <measurement group_id="O3" value="7.03" lower_limit="6.6" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg</title>
        <time_frame>Baseline, Week 4, and Week 8</time_frame>
        <population>Plasma concentration obtained after temporarily dosing discontinuation or not matched with the following conditions were excluded from the analysis; Steady-state condition: at least 80% drug compliance from the previous visit to the day of sampling; Trough condition: samples taken within ±10% of 24 hours from last dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>After once daily administration of amlodipine 5 mg for 8 weeks in the screening period</description>
          </group>
          <group group_id="O2">
            <title>Week 4</title>
          </group>
          <group group_id="O3">
            <title>Week 8</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg</title>
          <population>Plasma concentration obtained after temporarily dosing discontinuation or not matched with the following conditions were excluded from the analysis; Steady-state condition: at least 80% drug compliance from the previous visit to the day of sampling; Trough condition: samples taken within ±10% of 24 hours from last dosing.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.18" lower_limit="6.7" upper_limit="7.7"/>
                    <measurement group_id="O2" value="16.9" lower_limit="15.7" upper_limit="18.1"/>
                    <measurement group_id="O3" value="16.9" lower_limit="15.7" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

